Cover Image
市場調查報告書

心室心搏過速:開發中產品分析

Ventricular Tachycardia - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 361629
出版日期 內容資訊 英文 43 Pages
訂單完成後即時交付
價格
Back to Top
心室心搏過速:開發中產品分析 Ventricular Tachycardia - Pipeline Review, H1 2016
出版日期: 2016年05月31日 內容資訊: 英文 43 Pages
簡介

本報告提供全球各國治療心室心搏過速 (心室性心搏過速) 所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,並彙整主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

  • 簡介
    • 分析範圍
  • 心室心搏過速概要
  • 治療藥的開發
    • 心室心搏過速的開發中產品:概要
  • 心室心搏過速:各企業開發中的治療藥
  • 開發中產品的概要
    • 後期階段的產品
    • 初期階段的產品
  • 心室心搏過速:各企業開發中的產品
  • 心室心搏過速的治療藥開發企業
    • Audentes Therapeutics, Inc.
    • Gilead Sciences, Inc.
    • HUYA Bioscience International, LLC
    • Milestone Pharmaceuticals, Inc.
    • Perrigo Company Plc
  • 治療藥的評估
    • 單劑治療藥的情況
    • 標的別
    • 各作用機制
    • 投藥各途徑
    • 各分子類型
  • 藥物簡介
    • 唉呀榴蓮果鈉
      • 產品概要
      • 作用機制
      • 研究開發 (R&D)的進展
    • AT-307
    • eleclazine
    • etripamil
    • GS-967
    • HBI-3000
    • landiolol
  • 近幾年的開發平台趨勢
  • 開發暫停的計劃
  • 中止開發的計劃
  • 值得注意的最新趨勢·新聞稿 (全5件)
  • 附錄

圖表一覽

目錄
Product Code: GMDHC8131IDB

Summary

Global Markets Direct's, 'Ventricular Tachycardia - Pipeline Review, H1 2016', provides an overview of the Ventricular Tachycardia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ventricular Tachycardia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ventricular Tachycardia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Ventricular Tachycardia
  • The report reviews pipeline therapeutics for Ventricular Tachycardia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Ventricular Tachycardia therapeutics and enlists all their major and minor projects
  • The report assesses Ventricular Tachycardia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Ventricular Tachycardia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Ventricular Tachycardia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Ventricular Tachycardia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Ventricular Tachycardia Overview
  • Therapeutics Development
    • Pipeline Products for Ventricular Tachycardia - Overview
  • Ventricular Tachycardia - Therapeutics under Development by Companies
  • Ventricular Tachycardia - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Ventricular Tachycardia - Products under Development by Companies
  • Ventricular Tachycardia - Companies Involved in Therapeutics Development
    • Audentes Therapeutics, Inc.
    • Gilead Sciences, Inc.
    • HUYA Bioscience International, LLC
    • Milestone Pharmaceuticals, Inc.
    • Perrigo Company Plc
  • Ventricular Tachycardia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • aladorian sodium - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AT-307 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • eleclazine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • etripamil - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GS-967 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HBI-3000 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • landiolol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Ventricular Tachycardia - Recent Pipeline Updates
  • Ventricular Tachycardia - Dormant Projects
  • Ventricular Tachycardia - Product Development Milestones
    • Featured News & Press Releases
      • Jan 25, 2016: Milestone Pharmaceuticals Announces USAN Approval of Generic Name "Etripamil" for its Phase 2 Clinical Development Product for the Treatment of Paroxysmal Supraventricular Tachycardia
      • Jan 12, 2015: Milestone Pharmaceuticals Receives FDA Clearance of MSP-2017 Phase 2 IND
      • Nov 24, 2014: Milestone Announces Positive Phase 1 Data for MSP-2017; Supports Advancement into Phase 2 in PSVT Patients
      • May 09, 2014: Gilead Announces Phase 1 Data for Investigational Therapy, GS-6615, in Patients with Long QT-3 Syndrome
      • Oct 28, 2013: Milestone Pharmaceuticals Initiates a Phase 1 Clinical Trial with MSP-2017
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Ventricular Tachycardia, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Ventricular Tachycardia - Pipeline by Audentes Therapeutics, Inc., H1 2016
  • Ventricular Tachycardia - Pipeline by Gilead Sciences, Inc., H1 2016
  • Ventricular Tachycardia - Pipeline by HUYA Bioscience International, LLC, H1 2016
  • Ventricular Tachycardia - Pipeline by Milestone Pharmaceuticals, Inc., H1 2016
  • Ventricular Tachycardia - Pipeline by Perrigo Company Plc, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Ventricular Tachycardia Therapeutics - Recent Pipeline Updates, H1 2016
  • Ventricular Tachycardia - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Ventricular Tachycardia, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top